Related Papers
BMC Infectious Diseases
Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective
2018 •
Francesco Menzella
Background Empirical antibiotic coverage for atypical pathogens in community-acquired pneumonia (CAP) has long been debated, mainly because of a lack of epidemiological data. We aimed to assess both testing for atypical pathogens and their prevalence in hospitalized patients with CAP worldwide, especially in relation with disease severity. Methods A secondary analysis of the GLIMP database, an international, multicentre, point-prevalence study of adult patients admitted for CAP in 222 hospitals across 6 continents in 2015, was performed. The study evaluated frequency of testing for atypical pathogens, including L. pneumophila, M. pneumoniae, C. pneumoniae, and their prevalence. Risk factors for testing and prevalence for atypical pathogens were assessed through univariate analysis. Results Among 3702 CAP patients 1250 (33.8%) underwent at least one test for atypical pathogens. Testing varies greatly among countries and its frequency was higher in Europe than elsewhere (46.0% vs. 12....
American Journal of Respiratory and Critical Care Medicine
A Worldwide Perspective of Atypical Pathogens in Community-acquired Pneumonia
2007 •
Carlos Luna
European Journal of Clinical Microbiology & Infectious Diseases
Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study
2020 •
Daniela Chirita
Clinical Infectious Diseases
Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients
2018 •
kondwelani mateyo
Background The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia. Methods We conducted a secondary analysis of an international, multicenter study enrolling adult patients coming from the community with pneumonia and hospitalized in 222 hospitals in 54 countries worldwide. Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation, chronic steroid use, and solid tumor. Results At least 1 risk factor for immunocompromise was recorded in 18% of the 3702 patients enrolled. The prevalences of risk factors significantly differed across continents and countries, with chronic steroid use (45%), hematological cancer (25%), and chemotherapy (22%) the most common. Among immunocompromised patients, community-acquired pneumonia (CA...
European Journal of Internal Medicine
An international perspective on hospitalized patients with viral community-acquired pneumonia
2018 •
Katherine Reyes
ERJ open research
Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study
2018 •
Francesco Blasi
This study aimed to describe real-life microbiological testing of adults hospitalised with community-acquired pneumonia (CAP) and to assess concordance with the 2007 Infectious Diseases Society of America (IDSA)/American Thoracic Society (ATS) and 2011 European Respiratory Society (ERS) CAP guidelines. This was a cohort study based on the Global Initiative for Methicillin-resistant Pneumonia (GLIMP) database, which contains point-prevalence data on adults hospitalised with CAP across 54 countries during 2015. In total, 3702 patients were included. Testing was performed in 3217 patients, and included blood culture (71.1%), sputum culture (61.8%), urinary antigen test (30.1%), pneumococcal urinary antigen test (30.0%), viral testing (14.9%), acute-phase serology (8.8%), bronchoalveolar lavage culture (8.4%) and pleural fluid culture (3.2%). A pathogen was detected in 1173 (36.5%) patients. Testing attitudes varied significantly according to geography and disease severity. Testing was ...
Chest
Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia
2021 •
Ricardo Buitrago
Journal of Infection
International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia
2019 •
Nilam Soni
The Lancet. Infectious diseases
Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study
2016 •
bertrand hugo mbatchou ngahane
Antibiotic resistance is a major global health problem and pathogens such as meticillin-resistant Staphylococcus aureus (MRSA) have become of particular concern in the management of lower respiratory tract infections. However, few data are available on the worldwide prevalence and risk factors for MRSA pneumonia. We aimed to determine the point prevalence of MRSA pneumonia and identify specific MRSA risk factors in community-dwelling patients hospitalised with pneumonia. We did an international, multicentre study of community-dwelling, adult patients admitted to hospital with pneumonia who had microbiological tests taken within 24 h of presentation. We recruited investigators from 222 hospitals in 54 countries to gather point-prevalence data for all patients admitted with these characteristics during 4 days randomly selected during the months of March, April, May, and June in 2015. We assessed prevalence of MRSA pneumonia and associated risk factors through logistic regression analy...
The European respiratory journal
{"__content__"=>"Burden and Risk Factors for Community-acquired Pneumonia: a Multinational Point Prevalence Study of Hospitalised Patients.", "i"=>{"__content__"=>"Pseudomonas aeruginosa"}}
2018 •
Nilam Soni
is a challenging bacterium to treat due to its intrinsic antibiotic resistance to the most frequently used antibiotics in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with -CAP are limited. We assessed the multinational burden and specific risk factors associated with CAP.We enrolled 3,193 patients in 54 countries with confirmed diagnosis of CAP that underwent microbiological testing at admission. Prevalence was calculated according to the identification of Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant CAP.The prevalence of and antibiotic-resistant CAP was 4.2% and 2.0%, respectively. The rate of CAP in patients with prior infection/colonisation due to and at least one of the three independently associated chronic lung diseases [ tracheostomy, bronchiectasis and/or very severe COPD]) was 67%. In contrast, the rate of CAP was 2% in patients without prior ...
